# Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

> **NCT01525966** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 67 (actual)

## Conditions studied

- Inflammatory Breast Cancer
- Stage IIA Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Triple-negative Breast Cancer
- Stage IIB Breast Cancer
- Estrogen Receptor Negative
- Progesterone Receptor Negative
- HER2/Neu Negative

## Interventions

- **DRUG:** carboplatin
- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01525966
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-02-15
- **Primary completion:** 2019-01-11
- **Final completion:** 2026-11-11
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01525966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01525966, "Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01525966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*